

Special Issue

Drug Resistance in Targeted Cancer Therapy

Message from the Guest Editors

The present issue deals with the pharmacology of the most promising compounds targeting the key oncogenic pathways implicated in the development and progression of many tumor types through multiple effects on cell cycle progression, apoptosis, and invasion. Remarkably, they use a highly overlapping repertoire of signalling adaptors and downstream pathways, and are potential targets for different drugs.

Therefore, this Special Issue will provide readers working in the basic biomedical sciences as well as clinicians a comprehensive overview of novel effective anticancer compounds, with the aim of clarifying their development, pharmacology, resistance factors, and new strategies and applications, against major tumors.

Prof. Dr. Patricia Diana

Guest Editors

Prof. Dr. Elisa Giovannetti


Department of Medical Oncology, Cancer Center Amsterdam, VU University medical center, Amsterdam, The Netherlands

Prof. Dr. Patrizia Diana

Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi, 32-90123 Palermo, Italy

Deadline for manuscript submissions

closed (15 November 2019)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/19966

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).